Patents Examined by Janet Andres
  • Patent number: 8779144
    Abstract: Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 15, 2014
    Assignee: Evotec (US) Inc.
    Inventors: Michael G. Kelly, John Kincaid, Yeyu Cao, Carl Kaub, Sumithra Gowlugari, Jianhua He
  • Patent number: 8637675
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Patent number: 8633317
    Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: January 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Patent number: 8624024
    Abstract: Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: January 7, 2014
    Assignees: National University Corporation Nagoya University, Sekisui Medical Co., Ltd.
    Inventors: Kazuaki Ishihara, Manabu Hatano, Takashi Miyamoto
  • Patent number: 8618304
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are pharmaceutically active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: December 31, 2013
    Assignee: Sanofi
    Inventors: Josef Pernerstorfer, Heinz-Werner Kleemann, Matthias Schaefer, Alena Safarova, Marcel Patek
  • Patent number: 8618299
    Abstract: MCH-1 receptor antagonists are disclosed having the general formula These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: December 31, 2013
    Assignee: Albany Molecular Research, Inc.
    Inventors: Peter R. Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang
  • Patent number: 8618305
    Abstract: The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3 -(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: December 31, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad, Sachin Deorao Zade, Ajay Shankar Singh
  • Patent number: 8614329
    Abstract: The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: December 24, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Patent number: 8614325
    Abstract: This invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: December 24, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Xiaoqing Yang, Sara Sabina Hadida Ruah, Peter Diederik Jan Grootenhuis, Fredrick F. Van Goor, Martyn Curtis Botfield, Gregor Zlokarnik
  • Patent number: 8614323
    Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: December 24, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Masaya Kokubo, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
  • Patent number: 8604208
    Abstract: The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: December 10, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Patent number: 8604211
    Abstract: Molecules according to Formula One: and their uses are disclosed herein.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: December 10, 2013
    Assignee: Dow AroSciecnes, LLC.
    Inventors: Marshall H. Parker, Maurice C. H. Yap, Joseph D. Eckelbarger, Ann M. Buysse, Jonathan M. Babcock, Ricky Hunter, Yelena Adelfinskaya, Jack G. Samaritoni, Negar Garizi, Tony K. Trullinger
  • Patent number: 8598154
    Abstract: The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: December 3, 2013
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Robin Clark, Tony Johnson, Hazel Hunt, Ian McDonald
  • Patent number: 8598362
    Abstract: Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 3, 2013
    Assignee: ImmunoGen, Inc.
    Inventors: Wei Li, Robert Yongxin Zhao
  • Patent number: 8598354
    Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: December 3, 2013
    Assignees: University of South Florida, Medicines for Malaria Venture
    Inventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
  • Patent number: 8598369
    Abstract: The instant invention pertains to novel bi- or tricyclic sterically hindered alkoxyamines, their precursors, a process for their preparation and their use as light stabilizers for polymers or coatings, as flame retardants, as peroxide substitutes (rheology modifiers) or carbon radical scavengers.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: December 3, 2013
    Assignee: BASF SE
    Inventors: Stefan Hauck, Walter Fischer, Kai-Uwe Schöning
  • Patent number: 8592395
    Abstract: The present invention relates to compounds of Formula (I) and (Ia) useful in the treatment of CCR5-related diseases and disorders, for example, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: November 26, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Maosheng Duan, Wieslaw Mieczyslaw Kazmierski, Matthew Tallant
  • Patent number: 8592383
    Abstract: The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xianhai Huang, Jason Brubaker, Scott L. Peterson, John W. Butcher, Joshua T. Close, Michelle Martinez, Rachel Nicola MacCoss, Joon O. Jung, Phieng Siliphaivanh, Hongjun Zhang, Robert G. Aslanian, Purakkattle Johny Biju, Li Dong, Ying Huang, Kevin D. McCormick, Anandan Palani, Ning Shao, Wei Zhou
  • Patent number: 8592589
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 26, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Patent number: 8592629
    Abstract: This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes. These compounds are inhibitors of Nav1.7.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 26, 2013
    Assignee: Pfizer Limited
    Inventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier